Catalyst calendar
The repricing schedule is mostly public if you actually look at it.
AllI · Sterile fill-finish capacityII · Stoppers, syringes & drug-contact componentsIII · Pharmaceutical glass & vialsIV · Bioprocessing consumables & resinsV · API & small-molecule reshoringVI · CDMO capacity & the China exodusVII · Peptide & oligonucleotide manufacturingVIII · Sterile injectables & shortage economicsIX · Analytical instruments & QC releaseX · Private giants & exposure vehicles
High-impact · next 30 days
- 2026-07-31Section 232 pharmaceutical tariffs take effect (100% on patented pharma & APIs)
July 2026
- 31highPolicySection 232 pharmaceutical tariffs take effect (100% on patented pharma & APIs)The tariff carves out generics, biosimilars and orphan drugs, so it tests how much reshoring pressure actually reaches the generic-API choke versus only patented-drug supply chains.
August 2026
- 06mediumEarningsHKMPYHikma Pharmaceuticals H1 2026 interim resultsUpdates on the $1B US sterile-injectable expansion show whether announced domestic capacity is converting toward operational output in the generic-injectable choke.
October 2026
- 06lowConferenceCPhI Worldwide 2026, Fiera Milano (Oct 6-8)The largest global API/CDMO sourcing event where reshoring capacity announcements and qualified-supplier deals for non-Chinese API surface and reprice the bench.
December 2026
- 31highPolicyOMB statutory deadline to publish BIOSECURE list of biotechnology companies of concernNaming the companies of concern is the moment the BIOSECURE Act becomes operationally binding, repricing both Chinese CDMOs and their non-Chinese substitutes for US-API work.